Using two complementary models, i.e. cancer cells treated with nutlin-3 as clinically relevant paradigm of pharmacological reactivation of p53 in cancers, and Mdm2 hypomorphic mice as in vivo model of normal p53 functioning, we have demonstrated that activation of p53 evokes major changes in cellular phospholipid profiles. Here, MDM2 is linked to cancer.